The Soft Tissue Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Soft Tissue Sarcoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Soft Tissue Sarcoma Market.
Some of the key takeaways from the Soft Tissue Sarcoma Pipeline Report:
Companies across the globe are diligently working toward developing novel Soft Tissue Sarcoma treatment therapies with a considerable amount of success over the years.
Soft Tissue Sarcoma companies working in the treatment market are OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc., Lyvgen Biopharma Holdings Ltd., Chipscreen Biosciences, Ltd., Monopar Therapeutics, Advenchen Laboratories, LLC, Philogen S.p.A., Philogen, Nanobiotix, Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, and others, are developing therapies for the Soft Tissue Sarcoma treatment
Emerging Soft Tissue Sarcoma therapies in the different phases of clinical trials are- OTSA101-DTPA111In, FHD-609, CFT8634, LVGN6051 + Anlotinib, Chiauranib, MNPR 201, AL3818, Fibronum + Doxorubicin, L19 TNF, NBTXR3, GPX-150, LTX-315, Lurbinectedin, and others are expected to have a significant impact on the Soft Tissue Sarcoma market in the coming years.
In October 2022, The Spanish Agency for Medicines and Health Products (Agencia Espanola de Medicamentos y Productos Sanitarios, AEMPS) has approved a Phase 1b/randomized Phase 2 study comparing the effectiveness of doxorubicin alone versus doxorubicin plus LB-100, the company’s lead clinical compound, for the initial treatment of advanced soft tissue sarcomas (ASTS).
In September 2022, In order to facilitate an investigator-initiated open-label Phase II clinical trial, Immutep Limited is happy to announce that it has executed a Material Transfer Agreement (“Agreement”) with the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, Poland. Up to 40 patients with select soft tissue sarcoma (STS) will participate in the trial to assess Immutep’s principal product candidate, efti, in combination with pembrolizumab and radiation in the neoadjuvant situation (before to surgery).
In September 2022, The FDA has given envafolimab (KN035) fast-track designation for the treatment of patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy, according to TRACON Pharmaceuticals, Inc.
In September 2022, The leading pre|CISION medicine candidate for the firm, AVA6000, for the treatment of soft tissue sarcoma, received Orphan medicine Designation (ODD) from the US Food and Drug Administration (FDA), according to an announcement from Avacta Group plc.The generic chemotherapeutic medication doxorubicin has been altered to take the form AVA6000, which is activated primarily in the tumour in order to protect healthy tissue from exposure and enhance the medicine’s safety, tolerability, and effectiveness.
In May 2022, Immix Biopharma, Inc. released encouraging interim study results showing that in a study using mice with the connective tissue cancer Soft Tissue Sarcoma (STS), ImmixBio’s lead candidate IMX-110 produced 75% survival vs. 0% survival for Trabectedin (marketed as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA-approved drug). In this study, IMX-110 was contrasted with approved STS treatment options. The dosage of trabectedin was carried out in accordance with Meco et al., 2003 (trabectedin monotherapy treatment arm), and 2.0 mg/kg of IMX-110 was given.
In April 2022, According to a licence agreement between Telix Pharmaceuticals Limited and Eli Lilly and Company (“Lilly”), Telix has been given the sole worldwide right to create and market radiolabelled versions of Lilly’s olaratumab antibody for the detection and treatment of human cancers. Soft tissue sarcoma (STS), a rare form of cancer, will be the primary focus of Telix’s initial development efforts.
Soft Tissue Sarcoma Overview
A uncommon kind of cancer called soft tissue sarcoma starts in the tissues that surround, connect, and support other body structures. This consists of your muscle, fat, blood vessels, nerves, tendons, and joint lining. Soft tissue sarcomas come in more than 50 different varieties.While certain varieties primarily affect adults, others are more likely to afflict youngsters.
Get a Free Sample PDF Report to know more about Soft Tissue Sarcoma Pipeline Therapeutic Assessment-
Emerging Soft Tissue Sarcoma Drugs Under Different Phases of Clinical Development Include:
OTSA101-DTPA111In: OncoTherapy Science, Inc.
FHD-609: Foghorn Therapeutics Inc.
CFT8634: C4 Therapeutics, Inc.
LVGN6051 + Anlotinib: Lyvgen Biopharma Holdings Limited
Chiauranib: Chipscreen Biosciences, Ltd.
MNPR 201: Monopar Therapeutics
AL3818: Advenchen Laboratories, LLC
Fibronum + Doxorubicin: Philogen S.p.A.
L19 TNF: Philogen
GPX-150: Monopar Therapeutics
LTX-315: Lytix Biopharma
Lurbinectedin: Jazz Pharmaceuticals
Soft Tissue Sarcoma Route of Administration
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Soft Tissue Sarcoma Molecule Type
Soft Tissue Sarcoma Products have been categorized under various Molecule types, such as
Soft Tissue Sarcoma Pipeline Therapeutics Assessment
Soft Tissue Sarcoma Assessment by Product Type
Soft Tissue Sarcoma By Stage and Product Type
Soft Tissue Sarcoma Assessment by Route of Administration
Soft Tissue Sarcoma By Stage and Route of Administration
Soft Tissue Sarcoma Assessment by Molecule Type
Soft Tissue Sarcoma by Stage and Molecule Type
DelveInsight’s Soft Tissue Sarcoma Report covers around 130+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Soft Tissue Sarcoma product details are provided in the report. Download the Soft Tissue Sarcoma pipeline report to learn more about the emerging Soft Tissue Sarcoma therapies
Some of the key companies in the Soft Tissue Sarcoma Therapeutics Market include:
Key companies developing therapies for Soft Tissue Sarcoma are – Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and others.
Soft Tissue Sarcoma Pipeline Analysis:
The Soft Tissue Sarcoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
Soft Tissue Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Soft Tissue Sarcoma drugs and therapies
Soft Tissue Sarcoma Pipeline Market Drivers
Increase in Cancer Cases, rising Involvement of Clinical Trials are some of the important factors that are fueling the Soft Tissue Sarcoma Market.
Soft Tissue Sarcoma Pipeline Market Barriers
However, side-effects of Soft Tissue Sarcoma Drugs, increasing Cost Of Treatments and other factors are creating obstacles in the Soft Tissue Sarcoma Market growth.
Scope of Soft Tissue Sarcoma Pipeline Drug Insight
Key Soft Tissue Sarcoma Companies: OncoTherapy Science, Inc., Foghorn Therapeutics Inc., C4 Therapeutics, Inc., Lyvgen Biopharma Holdings Ltd., Chipscreen Biosciences, Ltd., Monopar Therapeutics, Advenchen Laboratories, LLC, Philogen S.p.A., Philogen, Nanobiotix, Monopar Therapeutics, Lytix Biopharma, Jazz Pharmaceuticals, and others
Key Soft Tissue Sarcoma Therapies: OTSA101-DTPA111In, FHD-609, CFT8634, LVGN6051 + Anlotinib, Chiauranib, MNPR 201, AL3818, Fibronum + Doxorubicin, L19 TNF, NBTXR3, GPX-150, LTX-315, Lurbinectedin, and others
Soft Tissue Sarcoma Therapeutic Assessment: Soft Tissue Sarcoma current marketed and Soft Tissue Sarcoma emerging therapies
Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma market drivers and Soft Tissue Sarcoma market barriers
Request for Sample PDF Report for Soft Tissue Sarcoma Pipeline Assessment and clinical trials
Table of Contents
1. Soft Tissue Sarcoma Report Introduction
2. Soft Tissue Sarcoma Executive Summary
3. Soft Tissue Sarcoma Overview
4. Soft Tissue Sarcoma- Analytical Perspective In-depth Commercial Assessment
5. Soft Tissue Sarcoma Pipeline Therapeutics
6. Soft Tissue Sarcoma Late Stage Products (Phase II/III)
7. Soft Tissue Sarcoma Mid Stage Products (Phase II)
8. Soft Tissue Sarcoma Early Stage Products (Phase I)
9. Soft Tissue Sarcoma Preclinical Stage Products
10. Soft Tissue Sarcoma Therapeutics Assessment
11. Soft Tissue Sarcoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Soft Tissue Sarcoma Key Companies
14. Soft Tissue Sarcoma Key Products
15. Soft Tissue Sarcoma Unmet Needs
16 . Soft Tissue Sarcoma Market Drivers and Barriers
17. Soft Tissue Sarcoma Future Perspectives and Conclusion
18. Soft Tissue Sarcoma Analyst Views
20. About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Address:27 Drydock Ave S. Jones Blvd #2432
Country: United States